Unique ID issued by UMIN | UMIN000011708 |
---|---|
Receipt number | R000013688 |
Scientific Title | Pharmacokinetic Study of S-1 in Cancer Patients with Varying Degrees of Renal Dysfunction (SCHOLAR Study) |
Date of disclosure of the study information | 2013/09/27 |
Last modified on | 2018/08/30 10:43:37 |
Pharmacokinetic Study of S-1 in Cancer Patients with Varying Degrees of Renal Dysfunction
(SCHOLAR Study)
Pharmacokinetic Study of S-1 in Cancer Patients with Varying Degrees of Renal Dysfunction
(SCHOLAR Study)
Pharmacokinetic Study of S-1 in Cancer Patients with Varying Degrees of Renal Dysfunction
(SCHOLAR Study)
Pharmacokinetic Study of S-1 in Cancer Patients with Varying Degrees of Renal Dysfunction
(SCHOLAR Study)
Japan |
The renal failure patients scheduled to intake TS-1
Gastroenterology | Hepato-biliary-pancreatic medicine | Pneumology |
Hematology and clinical oncology | Gastrointestinal surgery | Hepato-biliary-pancreatic surgery |
Chest surgery | Breast surgery | Dental medicine |
Malignancy
NO
To develop a simple formula of TS-1 dosage to the patients having renal failure.
Pharmacokinetics
Exploratory
To figure Area Under The Curve by measuring 5-FU blood level of the patients having renal failure.
Safety within 24 hours after TS-1 intake
Interventional
Parallel
Non-randomized
Open -no one is blinded
Uncontrolled
3
Treatment
Medicine |
TS-1 is orally administered before breakfast and blood sample is obtained 7 times from day1 to day2.
CLcr>60
TS-1 is orally administered before breakfast and blood sample is obtained 7 times from day1 to day2.
59>CLcr>30
TS-1 is orally administered before breakfast and blood sample is obtained 7 times from day1 to day2.
29>CLcr>15
20 | years-old | <= |
Not applicable |
Male and Female
1) Stage 1 to 4 of renal function
2) Age over 20 at registration
3) dosing purpose does not matter
4) prior chemotherapy include TS-1 does not matter
5) The presence or absence of measurable lesion does not matter.
6) PS 0-2
7) oral intake
8) sufficient function of organs except renal function
WBC: >=3,000/mm3 and <=12,000/mm3
Neu:>=1,500/mm3
Platelet: >=100,000/mm3
Hem: >=10.0g/dl
AST(GOT): <= 100IU/l(or 150U/L if biliary drainage were present)
ALT(GPT): <= 100IU/l(or 150U/L if biliary drainage were present)
sT.bil: <=2.0mg/dl(or 3.0mg/dl if biliary drainage were present)
9) written informed consent
1) pulmonary fibrosis and interstitial pneumonia
2) diarrhea
3) active infection
4) require blood transfusion within 14 days
5) severe complications
6) massive abdominal and pleural effusion
7) Being treated with flucytosine.
8) mental disease
9) Any patients judged by the investigator to be unfit to participate in the study.
15
1st name | |
Middle name | |
Last name | Hiroya Takeuchi |
Keio University, school of medecine
Div. of Gastroenterology, Dept. of Surgery
35, Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-3353-6440
htakeuchi@a6.keio.jp
1st name | |
Middle name | |
Last name | Eisuke Booka |
Keio University, school of medecine
Div. of Gastroenterology, Dept. of Surgery
35, Shinanomachi, Shinjuku-ku, Tokyo, Japan
03-3353-6440
ebooka@a2.keio.jp
Keio University, School of Medicine, Div. of Gastroenterology, Dept.of Surgery.
None
Self funding
St. Marianna University, School of Medicine
Shinshu University, School of Medicine
NO
2013 | Year | 09 | Month | 27 | Day |
Published
Completed
2013 | Year | 09 | Month | 27 | Day |
2013 | Year | 09 | Month | 27 | Day |
2015 | Year | 03 | Month | 31 | Day |
2015 | Year | 03 | Month | 31 | Day |
2013 | Year | 09 | Month | 11 | Day |
2018 | Year | 08 | Month | 30 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013688